For most of the last twenty five years, supplier controls were something an FDA investigator reached on the way to something else. The Quality System Inspection Technique organised an inspection around four subsystems, and purchasing was not one of them. FDA’s own QSIT guide names them plainly: “Management Control; Corrective and Preventive Actions (CAPA) (with satellites Medical Device Reporting, Corrections and Removals, and Medical Device Tracking); Design Controls; and Production and Process Controls (P&PC) (with satellite Sterilization Process Controls).” Purchasing controls appears in that guide as a linkage, something the investigator checks while evaluating design or production, for example by verifying “purchasing controls and receiving acceptance activities regarding at least one component or raw material.”
That is no longer how it works. Since 2 February 2026, part 820 has incorporated ISO 13485:2016 by reference, and FDA inspects against a new compliance program, 7382.850. That program replaces the four subsystems with six QMS Areas, and one of them is Outsourcing and Purchasing. In the most common inspection model, the investigator evaluates at least one element in every one of the six.
Read that again, because it is the part most coverage has skipped. Supplier controls have moved from an area an investigator might reach to an area the inspection design says they will open. Every time.
This piece is for the people who own those files: supplier quality engineers, supplier quality managers, and the vendor management teams who sit alongside them. It sets out what genuinely changed, what only moved from one document to another, and what a well kept supplier file now needs to contain. If you are outside medical devices, the last section explains what transfers, because the underlying shift is not really a device story. And if you want the wider picture of how supplier management works in this sector first, our SRM for medical devices page is the place to start.
What changed, and what only moved
There is a lot of writing about the QMSR that reads as if every supplier requirement was rewritten. Most of it was not. The honest picture is that a small number of requirements genuinely tightened, a larger number were already familiar to anyone who held an ISO 13485 certificate, and one protection quietly disappeared.
Here is the comparison that matters for supplier controls.
| Topic | Under the old QSR (21 CFR 820.50) | Under the QMSR (ISO 13485:2016 clause 7.4) | Genuine change? |
|---|---|---|---|
| Evaluating and selecting suppliers | Manufacturers had to “Evaluate and select potential suppliers, contractors, and consultants on the basis of their ability to meet specified requirements, including quality requirements. The evaluation shall be documented.” | Criteria for evaluation and selection, based on the supplier’s ability to meet requirements, with records kept | Mostly moved. The obligation is the same shape. |
| How much control to apply | Type and extent of control defined “on the basis of the evaluation results” | Control proportionate to the risk the purchased product carries for the device | Yes. Risk is now the explicit yardstick. |
| Records of acceptable suppliers | “Establish and maintain records of acceptable suppliers, contractors, and consultants.” | Records of evaluation, plus re-evaluation and ongoing monitoring | Partly. The monitoring expectation is firmer. |
| Change notification from the supplier | Purchasing documents should, “where possible”, include an agreement that the supplier notify changes | An agreement that the supplier notifies changes before implementing them, scoped as applicable to the item | Yes. From a best effort to a stated expectation with timing attached. |
| Verifying what arrives | Handled through acceptance activities elsewhere in the QSR | Verification of purchased product, with the extent tied to risk | Mostly moved, with a clearer risk link. |
| Supplier audit reports during an inspection | Shielded. Section 820.180(c) exempted them from routine FDA review | No such exemption exists | Yes. This is the largest single change. |
Three rows carry the weight. Take them in turn.
Risk became the yardstick, not the evaluation result
The old rule asked you to set the type and extent of control on the basis of the evaluation results. In practice that produced a common pattern: a supplier scored well on the questionnaire, so they got light oversight, and a supplier scored poorly, so they got heavy oversight. It is a sensible instinct, but it measures the supplier rather than the exposure.
ISO 13485 asks a different question. The level of assessment and monitoring should be proportionate to the risk the purchased product carries for the device. A supplier with an immaculate record who makes a component in the patient contact path is not a low control supplier because they score well. They are a high control supplier who happens to perform well, which is a much better place to be, and the file should say so.
This is a distinction worth making out loud internally, because it changes who gets attention. If you already run risk based supplier segmentation, you have the machinery. What usually needs work is making the link legible: the tier, the reason for the tier, and the control activities that follow from it, all in one place rather than inferred across three systems. Our note on supplier segmentation models covers the tiering logic, and risk based supplier segmentation covers how to make the segmentation defensible rather than historical.
Change notification grew teeth
The old text was gentle. Purchasing documents should, where possible, include an agreement that the supplier notify the manufacturer of changes to the product or service that may affect the quality of the finished device. “Where possible” is an easy phrase to satisfy with a clause nobody monitors.
ISO 13485 asks for purchasing information to include, where the nature of the item makes it applicable, a written agreement that the supplier gives notice of changes before implementing them. Two independent readings of the clause agree on that shape, and both note the scoping. The standard itself is paywalled, so we are paraphrasing rather than quoting, and we would encourage anyone writing the clause to read clause 7.4.2 in their own copy.
The word doing the work is “before”. A notification that arrives with the shipment is not notice, it is news. Which means the clause is only as good as two things you control: a stated notice period per category, and a turnaround commitment of your own. A supplier who tells you about a resin change ninety days early and hears nothing for eleven weeks learns quickly that early notice costs them time and buys them nothing.
We wrote about how to draft clauses like this so they can actually be measured in supplier quality agreements: write clauses you can actually measure. The short version is that every clause needs a named record, a named owner and a review point, and change notification is the clause where that discipline pays back fastest.
The shield came down
This is the change with the sharpest practical edge, and FDA states it without ambiguity. Asked whether it can now review audit records, the agency’s QMSR FAQ answers: “Yes. The QMSR gives the FDA the authority to inspect management review, quality audits, and supplier audit reports. The exceptions that existed in the QS regulation at § 820.180(c) are not maintained in the QMSR.”
Supplier audit reports were, for a long time, one of the few places a quality team could write with complete candour. That is no longer the position. The useful response is not to write blander audit reports, which would waste the instrument. It is to close findings on the timeline your own procedure promises, so that any report an investigator reads comes with its closure evidence attached.
An open finding from fourteen months ago is a problem whether or not anyone reads it. What changed is only whether anyone reads it. Teams that already run supplier findings through a tracked corrective action loop are in good shape here; teams that keep audit findings in a spreadsheet beside the report are the ones with work to do. Our pages on supplier CAPA and corrective actions and digital supplier audits both deal with keeping the finding and its evidence in one thread.
Pull three supplier files
The fastest way to know where you stand is not a gap assessment. It is to pick three suppliers and open their files as an investigator would.
Choose them deliberately: one supplier of a component in the highest risk path, one supplier you onboarded in the last twelve months, and one long standing supplier nobody has looked at in years. That third one is where the interesting findings live.
For each, ask whether the file answers these questions without anyone having to go and ask a colleague.
| Question | What should be in the file | Common gap |
|---|---|---|
| Why is this supplier approved? | The evaluation record, with the criteria used and the date | Approval exists, criteria do not, or the criteria are a form with no thresholds |
| Why do they get this level of oversight? | The risk tier, the reason for it, and the control activities it drives | Tier is in a different system from the file, or was set once and never revisited |
| What exactly are they making, and where? | The parts and the named manufacturing site, with dates | Parts sit in the ERP, sites are in nobody’s system |
| What did we agree they would tell us? | The quality agreement, with the change notification clause and notice period | Agreement exists, notice period is “promptly” |
| Have they told us anything, and what did we do? | Change notifications received, with the review and the decision | Notifications arrive by email to one person |
| How have they performed? | Scorecard history, with the metric definitions used | Scores exist, definitions are disputed |
| What did the last audit find, and is it closed? | Audit report, findings, evidence of closure, dates | Report filed, closure evidence elsewhere or absent |
| When is the next look scheduled, and why then? | The re-evaluation date and the rule that set it | Annual for everyone, regardless of risk |
If three files answer all eight, you are in genuinely good shape and the rest of this is confirmation. If the third supplier answers four, you have found the work, and you have found it in a form you can cost.
Two of these deserve a note. The question about parts and sites is the one most likely to produce a blank look, because supplier records are almost always organised per vendor while the questions asked of them are about products. We set out how to build the supplier, site and part layer properly in the data model that answers product level questions. And the last question, on timing, is the one where “annual for everyone” quietly contradicts the proportionality principle the QMSR just made explicit. Building a cadence suppliers can earn sets out a merit based alternative.
Why this is good news for supplier quality teams
It is tempting to read a new inspection program as pure downside. We would argue the opposite, and not as a consolation.
Supplier quality has always been an unusually hard function to resource, because its best work is invisible. A change caught before it reached production, a second source qualified before it was needed, a finding closed before it became a complaint: none of these generate an event anyone outside the team sees. Budget follows visible things.
Outsourcing and Purchasing being one of six named areas in the inspection program changes that arithmetic. The work is now structurally visible to the regulator, which makes it structurally visible internally. A supplier quality manager asking for a system rather than a spreadsheet has a much shorter conversation in 2026 than they had in 2024, and the argument does not need to be dramatic. It is simply that the files will be opened, so they should be worth opening.
There is a second benefit that is easy to miss. Because part 820 now points at ISO 13485:2016, the file that satisfies an FDA investigator is very close to the file that satisfies your notified body under EU MDR, and very close to the file your ISO 13485 certification audit already looks at. One well built supplier record serving three audiences is a better outcome than three overlapping ones, and it is the same collect once, report many principle that applies across the EU supply chain regulations. For teams running both markets, that convergence is the quiet win of the whole exercise.
What good looks like in the record layer
None of this requires a large programme. It requires that a handful of things stop living in email and start living somewhere with a date attached.
The change notification intake is the clearest example. A clause requiring notice before implementation creates an inbound flow, and an inbound flow with no defined destination becomes one engineer’s inbox. What it needs is an entry point suppliers can use without asking who to email, a triage step, a record of the decision, and a timestamp on each. That is the whole mechanism, and it is the difference between a clause you can evidence and a clause you can only assert. A supplier portal is the ordinary way to give that flow a front door, and automated follow up is what stops the triage step from depending on someone remembering.
The same logic applies to the other records in the eight question table. The audit finding and its closure evidence belong in one thread, not two systems. The risk tier belongs next to the controls it justifies, not in a separate segmentation file. The evaluation criteria belong with the evaluation, so that a decision made three years ago can still be explained by someone who was not there. Moving from annual reviews to continuous monitoring is what keeps those records current rather than merely complete. Supplier information management is the shape of that, and a full audit trail is what turns a set of records into something you can hand over.
If your supplier records currently live across a shared drive, a questionnaire tool and a spreadsheet of approvals, the honest first move is consolidation rather than sophistication. Replacing spreadsheets for supplier management covers that step without overselling it.
If you are not a device manufacturer
The specific rule is a device rule. The pattern is not.
Regulators and standards bodies have been converging for several years on the same idea: that oversight of external providers should scale to the risk those providers introduce, and that the oversight should be evidenced rather than asserted. The control of external providers in ISO 9001:2026 carries the same logic into general manufacturing. IATF 16949 has long expected it in automotive, where the scorecard requirements are unusually specific. The pharmaceutical equivalents sit in GMP chapter 7 on outsourced activities, and our SRM for pharma page covers how that plays out in practice.
So the three file test transfers directly. Pick three suppliers, open their files, and see whether each one explains why the supplier is approved, why they get the oversight they get, what you agreed they would tell you, and what happened the last time they told you something. If those four questions have answers with dates on them, the regulatory framework you happen to sit under matters much less than you would think.
Frequently asked questions
Does the QMSR require a supplier quality agreement? Not in those words. The requirement is that purchasing information includes an agreement, where applicable to the item, that the supplier gives notice of changes before implementing them. A quality agreement is simply the most practical place to put that, along with the metric definitions and the mutual obligations that make it workable. FDA’s own guidance on quality agreements in contract manufacturing recommends keeping them separate from commercial terms.
Do we have to requalify every supplier because of the QMSR? No, and any vendor telling you otherwise is selling something. Most of the evaluation and selection obligation moved rather than changed. The work is more usually in making existing decisions explainable: recording why a tier was set, attaching criteria to evaluations that have none, and closing audit findings that are open past their own due date.
Does FDA really read supplier audit reports now? The exemption that protected them at § 820.180(c) is not carried into the QMSR, and FDA has said directly that it has the authority to inspect them. Whether a given investigator asks for a particular report is a separate question from whether they may. Plan on the basis that they may.
We hold ISO 13485 certification already. How much of this is new? Less than for a company that ran purely to the QSR. The clause 7.4 obligations will be familiar. The genuinely new elements are the inspection structure, which puts Outsourcing and Purchasing on the agenda every time, and the loss of the audit report exemption, which is a US inspection matter rather than a standards matter.
Where should we start if the files are in poor shape? With three files, not with all of them. The three file test tells you which of the eight questions fail across different supplier types, and that tells you whether your problem is records, structure or cadence. Those are three different projects with three different costs, and guessing between them is how supplier programmes get oversized.
If you would like to see what a supplier record that answers all eight questions looks like in practice, our supplier performance pilot runs on a subset of your supply base so you can judge it against your own files, or you can book a demo and bring the awkward third supplier with you.
